Dr. David Lubaroff, Professor Emeritus, Emeritus Professor of Urology has received a UIRF GAP award of $75,000 to assist in advancing his prime-boost prostate cancer treatment method toward commercialization. The GAP project will confirm pervious positive research results, and complete several other critical proof of concept experiments. Successful completion of this project will enable licensing the IP to Ohana Vaccines, an early stage UIVentures startup.
This commercialization funding competition is designed to expand the commercialization of UI technologies. Funds are available to support the development of innovations with commercial potential through a range of stages in technology development, from initial concept, through proof of concept, to licensing and commercialization.
If the current trend holds, faculty at the University of Iowa will set yet another record year for licensed IP, invention disclosures, and patent applications filed in FY2015.
There were 104 patent application filings as of Feb. 28 compared with 83 last year, a 20 percent increase from FY2014; 96 disclosures compared with 71, up 26 percent; and 25 licenses and options compared with 19, up 25 percent.
Photo captions: Rives Bird, CEO of Iowa Adaptive Technologies (top), and the prototype for the noddle device
Iowa Adaptive Technologies Inc. (IAT), a University of Iowa startup that is developing devices and solutions to help critically ill and disabled patients take a more active role in communicating and participating in their own care, has signed an exclusive global licensing agreement with the UI Research Foundation (UIRF).